Alzamend Neuro, Inc.
ALZN evidence brief
What we can confirm
- BioSniper Score:
- 6.4 / 10
- Market Cap:
- $8.3M
- Cash Runway:
- 20.0 mo
What it means
What to watch
Prepared research question
What matters most for ALZN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ALZN
Alzamend Neuro, Inc. (ALZN) is a clinical-stage biopharmaceutical company developing two lead candidates, AL001 and ALZN002, for Alzheimer's disease and other psychiatric indications, with no approved products or near-term revenue.
Key risk: Insufficient cash runway
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jul 31, 2026.
Tracking 2 pipeline candidates · 3 clinical trials for Alzamend Neuro, Inc..
Similar companies
Alzamend Neuro, Inc. (ALZN) is a clinical-stage biopharmaceutical company developing two lead candidates, AL001 and ALZN002, for Alzheimer's disease and other psychiatric indications, with no approved products or near-term revenue.
- Alzamend is advancing two product candidates: AL001 for Alzheimer's, bipolar disorder (BD), major depressive disorder (MDD), and PTSD; and ALZN002 for Alzheimer's [sec_mda · as of 2026-09-10].
- As of 2026-07-31, the company reported cash & equivalents of $7.6M, net income of -$3.0M, and shareholders' equity of $5.8M [sec].
- The company has no source of near-term revenue and may never become profitable; it is at an early stage of clinical development [sec_mda · as of 2026-07-22].
- Alzamend completed the clinical portion of its first Phase 2 study of AL001 in healthy subjects in November 2025, with topline data expected in Q1 2026 [news · published 2025-11-19].
- The company's cash position as of April 30, 2026 was $711,000, which management stated would not be sufficient to fund operations for the next twelve months [sec_mda · as of 2026-07-22].
What works
- Alzamend has two active clinical programs (AL001 and ALZN002) targeting large markets including Alzheimer's, BD, MDD, and PTSD [sec_mda · as of 2026-09-10].
- The company completed the clinical portion of its first Phase 2 study for AL001 in healthy subjects, indicating progress in its pipeline [news · published 2025-11-19].
What to weigh
- Alzamend has no approved products, no near-term revenue, and may never become profitable [sec_mda · as of 2026-07-22].
- The company's cash position of $711,000 as of April 30, 2026 is insufficient to fund operations for the next twelve months, requiring substantial additional funding [sec_mda · as of 2026-07-22].
- Alzamend is at an early stage of clinical development and has not initiated or completed a pivotal clinical trial [sec_mda · as of 2026-07-22].
From the filings
Quoted directly from source documents.
Alzamend has no near-term revenue and may never become profitable.
“We are at an early stage of clinical development and currently have no source of near-term revenue and may never become profitable.”
SEC MD&A · July 22, 2026
Cash position as of April 30, 2026 was $711,000 and insufficient for twelve months.
“As of April 30, 2026, we had $711,000 in cash and cash equivalents. Based on our current operating plan, we believe that this funding will not be sufficient to fund our operations for the next twelve months.”
SEC MD&A · July 22, 2026
AL001 Phase 2 clinical portion completed in November 2025.
“Alzamend Neuro, Inc. (NASDAQ:ALZN) on Wednesday announced the completion of the clinical portion of its first Phase 2 clinical study of AL001 in healthy human subjects.”
News · November 19, 2025
Catalyst timeline
- 2023-07-05 · Phase 2 start for AL001 (healthy subjects) — Randomized, double-blind, placebo-controlled Phase 1/2a study of AL001 in mild-to-moderate Alzheimer's dementia.
- 2025-05-09 · Phase 1 start for AL001 (bioavailability study) — Phase 1 crossover study comparing lithium brain/plasma PK and safety of AL001 oral capsule vs. marketed lithium carbonate in healthy adults.
- 2026-05-11 · Phase 2 start for AL001 (healthy subjects) — Phase 1/2A multiple-dose crossover study of AL001 in healthy subjects.
Risks & what to watch (3)›
Key risks
- Insufficient cash runway — Cash of $711K as of April 30, 2026 is not enough to fund operations for twelve months [sec_mda · as of 2026-07-22].
- No approved products or revenue — Company has no source of near-term revenue and may never become profitable [sec_mda · as of 2026-07-22].
- Early-stage pipeline risk — No pivotal clinical trial initiated; success depends entirely on AL001 and ALZN002 development [sec_mda · as of 2026-07-22].
What to watch
- Topline data from the AL001 Phase 2 study in healthy subjects expected in Q1 2026 [news · published 2025-11-19].
- Initiation of Phase II clinical trials for AL001 in Alzheimer's, BD, MDD, and PTSD [sec_mda · as of 2026-07-22].
- Completion of the Phase I/IIA clinical trial for ALZN002 for mild to moderate Alzheimer's dementia [sec_mda · as of 2026-07-22].
- Ability to raise additional capital to fund operations beyond the current cash runway [sec_mda · as of 2026-07-22].
Sources: Catalysts · News · SEC MD&A · Generated October 1, 2026 · How we verify sources →
Run Alzamend Neuro, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Alzamend Neuro, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
20.0 months
D/E 0.47 · 0% dilution
Lead: Phase 1/Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
12
Total value held
$122K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 45,680 | $48K |
| vanguard fiduciary trust co | 21,020 | $22K |
| morgan stanley | 18,000 | $19K |
| clearstead advisors, llc | 10,000 | $11K |
| tower research capital llc (trc) | 6,184 | $7K |
| citigroup inc | 5,231 | $6K |
| ubs group ag | 4,504 | $5K |
| vanguard capital management llc | 4,400 | $5K |
| blackrock, inc. | 437 | $463 |
| sbi securities co., ltd. | 22 | $23 |
Showing top 10 of 12 institutional holders of Alzamend Neuro, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 5.4%
- Days to cover
- 2.4
- Shares short
- 204,743
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ALZN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Alzamend Neuro, Inc.?
Alzamend Neuro, Inc. (ALZN) is a clinical-stage biopharmaceutical company developing two lead candidates, AL001 and ALZN002, for Alzheimer's disease and other psychiatric indications, with no approved products or near-term revenue.
What is Alzamend Neuro, Inc.'s lead drug candidate?
Alzamend Neuro, Inc.'s most advanced tracked candidate is AL001 (Phase 1/Phase 2) for Pharmacokinetics; Bipolar I Disorder.
Who is the CEO of Alzamend Neuro, Inc.?
Mr. Stephan Jackman is the chief executive officer of Alzamend Neuro, Inc. (ALZN).
Where is Alzamend Neuro, Inc. headquartered?
Alzamend Neuro, Inc. (ALZN) is headquartered in Atlanta, GA, United States.
What therapeutic areas does Alzamend Neuro, Inc. focus on?
Alzamend Neuro, Inc. develops therapies across Oncology, Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.